Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 20, 2017 12:12 ET | Source: Achillion Pharmaceuticals, Inc.

CORRECTION - Achillion Pharmaceuticals, Inc.

NEW HAVEN, Conn., Dec. 20, 2017 (GLOBE NEWSWIRE) -- In the news release issued earlier today by Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), please be advised the headline should read "Achillion...
December 20, 2017 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Initiates Phase I First-In Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D

NEW HAVEN, Conn., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a pharmaceutical company focused on advancing small molecule inhibitors of factor D in the...
December 18, 2017 06:30 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces ACH-4471 Granted Orphan Drug Designation for the Treatment of C3 Glomerulopathy (C3G) and the Initiation of a Phase 1 Extended-Release Bioavailability Study

- Orphan drug designation for the treatment of C3G granted by the U.S. Food and Drug Administration (FDA) – - Initiated bioavailability study evaluating extended-release formulations of ACH-4471 in...
November 15, 2017 22:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Pricing of Secondary Offering Of Common Stock

NEW HAVEN, Conn., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (“Achillion”) (NASDAQ:ACHN) today announced the pricing of an underwritten public offering of 18,367,346 shares of...
November 14, 2017 16:03 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Proposed Secondary Offering of Common Stock

NEW HAVEN, Conn., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (“Achillion”) (NASDAQ:ACHN) today announced that Johnson & Johnson Innovation-JJDC, Inc. (“JJDC”), an existing...
November 14, 2017 16:01 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports Preliminary Proof-of-Concept With ACH-4471 for the Treatment of C3G

- Greater than 50% improvement in proteinuria (albumin to creatinine ratio) after 14 days of oral dosing with ACH-4471 - - Improvement in complement alternative pathway biomarkers observed - ...
November 06, 2017 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces ACH-4471 Granted Orphan Drug Designation by the FDA and Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

NEW HAVEN, Conn., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation...
November 01, 2017 16:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs

NEW HAVEN, Conn., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three months ended September 30, 2017. For the third...
October 24, 2017 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

USPTO Grants Composition of Matter Patent to Achillion for ACH-4471, First-in-Class Small Molecule Complement Alternative Pathway Factor D Inhibitor

NEW HAVEN, Conn., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued a U.S. Patent to...
October 23, 2017 07:00 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Presentation of Data From OMEGA-1 Phase 2b Trial With Odalasvir, AL-335, and Simeprevir (JNJ-4178) at the 2017 Liver Meeting

NEW HAVEN, Conn., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) reported today Phase 2b data on JNJ-4178, the triple combination consisting of odalasvir, AL-335,...